343 related articles for article (PubMed ID: 34009296)
21. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
22. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
23. Regulation of FAS exon definition and apoptosis by the Ewing sarcoma protein.
Paronetto MP; Bernardis I; Volpe E; Bechara E; Sebestyén E; Eyras E; Valcárcel J
Cell Rep; 2014 May; 7(4):1211-26. PubMed ID: 24813895
[TBL] [Abstract][Full Text] [Related]
24. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
[TBL] [Abstract][Full Text] [Related]
25. Mithramycin A Radiosensitizes EWS:Fli1
Lin MY; Damron TA; Oest ME; Horton JA
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1454-1471. PubMed ID: 33373655
[TBL] [Abstract][Full Text] [Related]
26. Participation of nuclear localization signal 2 in the 3'-ETS domain of FLI1 in nuclear translocation of various chimeric EWS-FLI1 oncoproteins in Ewing tumor.
Honsei N; Ikuta T; Kawana K; Kaneko Y; Kawajiri K
Int J Oncol; 2006 Sep; 29(3):689-93. PubMed ID: 16865286
[TBL] [Abstract][Full Text] [Related]
27. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.
Apfelbaum AA; Wu F; Hawkins AG; Magnuson B; Jiménez JA; Taylor SD; Wrenn ED; Waltner O; Pfaltzgraff ER; Song JY; Hall C; Wellik DM; Ljungman M; Furlan SN; Ryan RJH; Sarthy JF; Lawlor ER
Clin Cancer Res; 2022 Oct; 28(20):4466-4478. PubMed ID: 35653119
[TBL] [Abstract][Full Text] [Related]
28. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
29. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
[TBL] [Abstract][Full Text] [Related]
30. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
31. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.
Shi X; Zheng Y; Jiang L; Zhou B; Yang W; Li L; Ding L; Huang M; Gery S; Lin DC; Koeffler HP
Nucleic Acids Res; 2020 Nov; 48(20):11434-11451. PubMed ID: 33080033
[TBL] [Abstract][Full Text] [Related]
32. Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone.
Park H; Turkalo TK; Nelson K; Folmsbee SS; Robb C; Roper B; Azuma M
Cell Cycle; 2014; 13(15):2391-9. PubMed ID: 25483190
[TBL] [Abstract][Full Text] [Related]
33. EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells.
Lu Q; Zhang Y; Ma L; Li D; Li M; Li J; Liu P
Int J Mol Med; 2017 Oct; 40(4):1217-1225. PubMed ID: 28902354
[TBL] [Abstract][Full Text] [Related]
34. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O
Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076
[TBL] [Abstract][Full Text] [Related]
35. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
[TBL] [Abstract][Full Text] [Related]
36. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
37. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
[TBL] [Abstract][Full Text] [Related]
38. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.
Erkizan HV; Uversky VN; Toretsky JA
Clin Cancer Res; 2010 Aug; 16(16):4077-83. PubMed ID: 20547696
[TBL] [Abstract][Full Text] [Related]
40. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.
Erkizan HV; Scher LJ; Gamble SE; Barber-Rotenberg JS; Sajwan KP; Üren A; Toretsky JA
Cell Cycle; 2011 Oct; 10(19):3397-408. PubMed ID: 21926473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
